Intranasal sumatriptan for the acute treatment of migraine in children.

Abstract

Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. Fourteen children with migraine (6.4 to 9.8 years of age; seven girls, six with aura) participated in a randomized double-blind placebo-controlled crossover study to evaluate the efficacy of sumatriptan nasal spray. After sumatriptan, 12 of 14 (versus 6 of 14 after placebo) reported a decrease in pain intensity (p = 0.031); complete headache relief was obtained in 9 of 14 after sumatriptan versus 2 of 14 after placebo (p = 0.016). Migraine-associated symptoms were also significantly reduced by sumatriptan.

• Authors: M A Ueberall, D Wenzel
• Journal: Neurology (Neurology) Vol. 52 Issue 7 Pg. 1507-10 (Apr 22 1999) ISSN: 0028-3878 [Print] United States
• PMID: 10227648 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Sumatriptan

Topics

• Administration, Intranasal
• Child
• Double-Blind Method
• Female
• Humans
• Male
• Migraine Disorders (drug therapy)
• Sumatriptan (administration & dosage, therapeutic use)